🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Reckitt Benckiser shares maintain Citi target despite legal concerns

EditorEmilio Ghigini
Published 30/07/2024, 08:06
RBGLY
-

On Tuesday, Citi maintained its Buy rating and GBP57.00 price target for Reckitt Benckiser (LON:RKT:LN) (OTC: RBGLY), following a recent legal development. A jury has awarded substantial damages against Abbott, with Reckitt Benckiser receiving a $60 million compensatory damages award. Citi's analysis includes a theoretical increase in Reckitt's liability overhang from USD4 billion to USD6 billion due to the verdict.

The implications of the jury's decision suggest potential delays for Reckitt Benckiser's planned exit from its Mead Nutrition business. Originally anticipated to occur before the first half of 2025, the timeline may now extend beyond this period. The extended litigation risk is expected to be a factor for any prospective buyers of the division.

Citi's assessment also indicates that the additional USD1.5 billion in potential liabilities could reduce Reckitt Benckiser's share price by GBP2 from its current valuation. Despite the litigation concerns and the complexities surrounding the Mead exit, the firm's valuation includes a conservative sum-of-parts (SOP) analysis, accounting for litigation, Home stranded costs, and tax.

The financial institution acknowledges the challenging environment for Reckitt Benckiser to navigate through the first half of 2025. The company's share price and market performance will likely be influenced by how it addresses these legal and operational challenges in the coming months.

InvestingPro Insights

As Reckitt Benckiser (OTC: RBGLY) faces extended litigation risks and potential delays in divesting its Mead Nutrition business, the company's financial metrics and management strategies become increasingly relevant to investors. According to real-time data from InvestingPro, Reckitt Benckiser boasts an adjusted market cap of $36.71 billion and an impressive gross profit margin of 60.56% for the last twelve months as of Q2 2024. The company's commitment to shareholders is evident, having maintained dividend payments for 33 consecutive years, with a current dividend yield of 3.6%. Despite a recent downturn in revenue growth, with a -4.55% change over the last twelve months as of Q2 2024, Reckitt Benckiser's management has been aggressively buying back shares, which could signal confidence in the company's future performance.

InvestingPro Tips highlight that while the stock is trading near its 52-week low, analysts predict the company will be profitable this year, having been profitable over the last twelve months. This could present a buying opportunity for long-term investors. For those looking to delve deeper into Reckitt Benckiser's prospects, additional InvestingPro Tips are available, offering a comprehensive analysis of potential investment strategies. To access these insights and more, investors can use coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, which includes a total of 8 InvestingPro Tips for Reckitt Benckiser.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.